自MR-T2图像勾画肝细胞癌患者放疗靶区精度研究

doi:10.3969/j.issn.1672-5069.2021.04.028

摘要/Abstract

摘要： 目的研究MRI-T2加权像扫描(MR-T2)图像对肝细胞癌(HCC)患者放疗靶区勾画精度的影响。方法 2019年5月～2020年5月我院诊治的36例HCC患者,在接受放疗前行CT和MRI检查,勾画大体肿瘤体积(GTV),经形变配准后获得大体内靶区(IGTV)和计划靶区(PTV)。应用Reg Refine图像形变配准。记录2%、50%、95%和98%PTV体积的受照剂量(分别记为D2、D50、D95和D98)。结果经Reg Refine配准后,门静脉x、y和z轴向位移分别为(0.5±0.2)mm、(0.8±0.3)mm和(0.7±0.3)mm,显著小于自动形变配准【分别为(2.9±0.4)mm、(4.8±0.5)mm和(3.9±0.6)mm,P<0.05】,腹腔干x、y和z轴向位移分别为(0.8±0.4)mm、(0.7±0.3)mm和(0.6±0.3)mm,显著小于自动形变配准【分别为(3.2±0.5)mm、(3.0±0.7)mm和(2.4±0.4)mm,P<0.05】;形变配准后GTV和IGTV分别为(379.8±103.9)cm³和(430.1±120.6)cm³,显著大于形变配准前【分别为(330.4±92.8)cm³和(375.2±95.5)cm³,P<0.05】, PTV为(542.7±130.2)cm³,显著小于形变配准前【(690.2±150.3)cm³,P<0.05】;形变配准后D2、D50、D95和D98靶区剂量分别为(56.0±12.9)Gy、(53.0±6.8)Gy、(49.8±5.3)Gy和(52.9±8.1)Gy,与形变配准前【(55.7±13.2)Gy、(52.8±7.3)Gy、(50.1±4.6)Gy和(53.3±7.7)Gy】比,差异均无统计学意义(P>0.05);形变配准后肝脏V5、V10、V20、V30和V40受照剂量分别为(52.7±9.4)%、(32.0±5.6)%、(20.1±4.6)%、(13.5±5.2)%和(7.4±3.8)%,显著低于配准前【分别为(58.2±10.1)%、(39.3±7.5)%、(24.8±5.8)%、(17.2±4.4)%和(10.1±3.9)%,P<0.05】。结论应用MR-T2图像勾画HCC放疗靶区有助于扩大靶区范围和运动轨迹,提高肝癌靶区勾画精度。

关键词: 肝细胞癌, MR-T2图像, 放疗, 靶区勾画精度

Abstract: Objective The aim of this study was to investigate the target delineation accuracy of tumors for radiotherapy based on MR-T2 image in patients with hepatocellular carcinoma (HCC). Methods 36 patients with HCC were enrolled in this study between May 2019 and May 2020, and all patients underwent CT and MRI scan before radiotherapy. The gross tumor volume (GTV), internal gross tumor target volume (IGTV) and planning target volume (PTV) as well as 2%, 50%, 95% and 98% exposure dose of PTV(D2, D50, D95 and D98) were recorded. Results The x, y and z axial displacements of portal vein after Reg refine registration were(0.5±0.2)mm, (0.8±0.3)mm and (0.7±0.3)mm, significantly smaller than [(2.9±0.4)mm,(4.8±0.5)mm and (3.9±0.6)mm, respectively, P<0.05] by automatic deformation registration, and the x, y and z axial displacements of celiac trunk were (0.8±0.4)mm, (0.7±0.3)mm and (0.6±0.3)mm, significantly smaller than [(3.2±0.5)mm, (3.0±0.7)mm and (2.4±0.4)mm, respectively, P<0.05] by automatic deformation registration; the GTV and IGTV after deformation registration were (379.8±103.9)cm³ and (430.1±120.6)cm³, significantly larger than [(330.4±92.8)cm³ and (375.2±95.5)cm³, P<0.05] before deformation registration, while the PTV was (542.7±130.2)cm³, significantly smaller than [(690.2±150.3)cm³, P<0.05] before deformation registration; the exposure doses of D2, D50, D95 and D98 target tumors after deformation registration were (56.0±12.9)Gy, (53.0±6.8)Gy, (49.8±5.3)Gy and (52.9±8.1)Gy, not significantly different compared to [(55.7±13.2)Gy, (52.8±7.3)Gy, (50.1±4.6)Gy and (53.3±7.7)Gy] before deformation registration(P>0.05); the V5, V10, V20, V30 and V40 exposure doses of liver after deformation registration were (52.7±9.4)%, (32.0±5.6)%, (20.1±4.6)%, (13.5±5.2)% and (7.4±3.8)%, significantly lower than [(58.2±10.1)%, (39.3±7.5)%, (24.8±5.8)%, (17.2±4.4)% and (10.1±3.9)%, P<0.05] before deformation registration. Conclusion The target delineation based on MR-T2 imaging for radiotherapy in patients with HCC could help expand the target area and trajectory, and improve the accuracy of target delineation, which might improve the radiotherapy efficacy.

Key words: Hepatoma, MR-T2 images, Radiotherapy, Target delineation accuracy

高金龙, 王海峰, 李娜, 梁朝晖, 张文正. 自MR-T2图像勾画肝细胞癌患者放疗靶区精度研究[J]. 实用肝脏病杂志, 2021, 24(4): 565-568.

Gao Jinlong, Wang Haifeng, Li Na, et al. Target delineation accuracy of tumors for radiotherapy based on MR-T2 image in patients with hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2021, 24(4): 565-568.

参考文献

[1] Yang D, Hanna D L, Usher J, et al. Impact of sex on the survival of patients with hepatocellular carcinoma: A surveillance, epidemiology, and end results analysis. Cancer, 2015, 120(23):3707-3716.
[2] Carville K S, Maclachlan J H, Vicky T, et al. Hepatocellular carcinoma over three decades in Victoria, Australia: epidemiology, diagnosis and trends, 1984-2013. Intern Med J, 2018,48(7):835-844.
[3] 曹艳,王艳.基于死因监测青岛市居民2008-2012年原发性肝癌死亡分析.中华肿瘤防治杂志,2017,24(9):579-583.
[4] Nabavizadeh N, Waller J G, Fain R, et al. Safety andefficacy of accelerated hypofractionation and stereotactic body radiotherapy for hepatocellular carcinoma patients with varying degrees of hepatic impairment. Int J Radiat Oncol Biol Phy, 2017, 100(3):577-585.
[5] Rajyaguru D J, Borgert A J, Smith A L, et al. Radiofrequencyablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: analysis of the national cancer database. J Clin Oncol, 2018, 36(6):600-608.
[6] Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol, 2017, 67( 1):92-99.
[7] Zhang Y D, Zhu F P, Xu X, et al. Classifying CT/MR findings in patients with suspicion of hepatocellular carcinoma: Comparison of liver imaging reporting and data system and criteria-free Likert scale reporting models.J Magn Reson Imaging, 2016, 43(2):373-383.
[8] 陈亮,段海峰,余红星.SMI、CDFI和增强CT检查TACE术治疗的原发性肝癌患者癌组织血供显像效果比较.实用肝脏病杂志,2020,23(1):90-93.
[9] Qiu G, Jin Z, Chen X, et al. Interpretation of guidelines for the diagnosis and treatment of primary liver cancer (2019 edition) in China. Glob Health Med, 2020, 2(5):306-311.
[10] Wang C, Yang L, Liang Z, et al. Long-term survival and prognostic factors of pulmonary metastasectomy in liver cancer: A systematic review and Meta-analysis. World J Surg, 2018,42(7):2153-2163.
[11] 耿冲, 孙苏平, 叶涛,等. 通过骨痛量表分析放疗前后肝癌骨转移患者的生活质量及影响因素. 中华放射医学与防护杂志, 2020,40(3):216-220.
[12] 邱健健,吕博,黄莹, 等.基于容积旋转弧形调强放疗技术的肝癌立体定向放疗方案评估与位置误差分析.中华放射医学与防护杂志,2017,37(2):143-148.
[13] Rades D, Bolm L, Schild S E, et al. Survival following palliative external-beam radiotherapy of locally advanced and metastatic liver cancer. Anticancer Res, 2017, 37(1):203-206.
[14] Bae S H, Kim M S, Jang W I, et al. Lowhepatic toxicity in primary and metastatic liver cancers after stereotactic ablative radiotherapy using 3 fractions. J Korean Med Sci, 2015, 30(8):1055-1061.
[15] Tanaka O, Nishigaki Y, Hayashi H, et al. The advantage of iron-containing fiducial markers placed with a thin needle for radiotherapy of liver cancer in terms of visualization on MRI: an initial experience of Gold Anchor. Radiol Case Rep, 2017, 12( 2):416-421.
[16] Sun L M, Lin C L, Lin M C, et al. Radiotherapy- andchemotherapy-induced myelodysplasia syndrome: A nationwide population-based nested case-control study. Medicine, 2015, 94(17):e737-e750.
[17] Li X D, Wang Z, Wang X R, et al. Berberine-loaded Janus gold mesoporous silica nanocarriers for chemo/radio/photothermal therapy of liver cancer and radiation-induced injury inhibition. Int J Nanomedicine, 2019(14):3967-3982.
[18] 夏文龙,陈波,黄鹏, 等.基于计划质量度量(PQM)量化比较有无均整器模式下肝癌容积旋转调强放疗计划.中华放射医学与防护杂志,2018,38(9):680-683.
[19] Hyun S, Bae G, Mi-Sook S, et al. Low hepatic toxicity in primary and metastatic liver cancers after stereotactic ablative radiotherapy using 3 fractions. J Korean Med Sci, 2015,30(8):1055-1061.